医学
免疫系统
巨噬细胞极化
纳米载体
炎症体
系统生物学
个性化医疗
生物信息学
计算生物学
免疫学
表观遗传学
免疫抑制
串扰
杠杆(统计)
生物
精密医学
人性化鼠标
炎症
免疫调节
免疫
作者
Wei Jiang,Huan Tang,Yan Hu,Jiayi Sun,Zhangrong Lou,Peng Qu,Qiang Liu
标识
DOI:10.1080/17425247.2026.2636761
摘要
INTRODUCTION: Atherosclerosis (AS) is a chronic inflammatory disease where lipid-lowering therapy alone leaves 30-40% residual cardiovascular risk, underscoring the need for immunomodulatory interventions. AREAS COVERED: This review synthesizes literature (1990-2024) on AS immunopathology and targeted nanomedicine. EXPERT OPINION: Key mechanisms include dysregulated macrophage polarization (M1/M2 imbalance), Th1/Treg dysfunction, NLRP3 inflammasome activation, and NETosis. Immunomodulatory strategies are shifting from broad immunosuppression toward subset-specific precision intervention - targeting mitochondrial fission (DRP1), ANGPTL3, or epigenetic regulators (SET7). Concurrently, nanodelivery systems have evolved from single-ligand targeting to smart, biomimetic platforms (e.g. VLA-4/VCAM-1 dual-targeting, ROS-responsive release) that enhance spatiotemporal precision. Emerging frontiers include immunometabolic crosstalk (cholesterol crystals activating cGAS-STING) and interventions disrupting immune cell communication (LNP-delivered NLRP3 siRNA, PAD4 inhibitors). Major challenges persist - suboptimal plaque penetration, hepatic nanocarrier accumulation, and risks of systemic immunosuppression. Future breakthroughs require dual-modal platforms integrating immunomodulation with metabolic reprogramming, and multi-omics-guided personalized systems that leverage spatial transcriptomics to tailor delivery to patient-specific inflammatory niches. Bridging the gap between mechanistic elegance and clinical efficacy demands humanized models and flexible trial designs.
科研通智能强力驱动
Strongly Powered by AbleSci AI